Format

Send to

Choose Destination
J Nucl Med. 2016 Dec;57(12):1941-1944. Epub 2016 Jul 7.

225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.

Author information

1
Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany clemens.kratochwil@med.uni-heidelberg.de.
2
European Commission, Joint Research Centre, Institute for Transuranium Elements, Karlsruhe, Germany.
3
Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
4
Department of Nuclear Medicine, RWTH University Hospital Aachen, Aachen, Germany; and.
5
Division of Radiopharmaceutical Chemistry, German Cancer Research Center, Heidelberg, Germany.

Abstract

Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human treatment with an α-radionuclide-labeled PSMA ligand. Although the case series is still ongoing, we here report in advance about two patients in highly challenging clinical situations who showed a complete response to 225Ac-PSMA-617 therapy.

METHODS:

68Ga-PSMA-11 PET/CT validated the presence of the PSMA-positive tumor phenotype. A 100-kBq activity of 225Ac-PSMA-617 per kilogram of body weight was administered bimonthly. Prostate-specific antigen response and hematologic toxicity were measured at least every 4 wk. Restaging was performed with 68Ga-PSMA-11 PET/CT.

RESULTS:

Both patients experienced a prostate-specific antigen decline to below the measurable level and showed a complete response on imaging. No relevant hematologic toxicity was observed. Xerostomia was the only mentionable clinical side effect.

CONCLUSION:

Targeted α-therapy with 225Ac-PSMA-617, although still experimental, obviously has strong potential to significantly benefit advanced-stage prostate cancer patients.

KEYWORDS:

225Ac; PSMA; alpha-therapy

PMID:
27390158
DOI:
10.2967/jnumed.116.178673
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center